Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2022 | ROR1 signaling & its potential as a therapeutic target for leukemia

Thomas Kipps, MD, PhD, UC San Diego, Moores Cancer Center, La Jolla, CA, highlights how inhibiting the ROR1 signaling pathway may represent a promising treatment strategy for chronic lymphocytic leukemia (CLL). Dr Kipps explains that, for instance, inhibiting the ROR1 signaling pathway would inhibit the expression of downstream matrix metalloproteinases that facilitate leukemic cell extravasation. Thus, inhibiting the ROR1 signaling pathway may increase leukemic cells’ susceptibility to death by host factors or by neglect. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

AbbVie: Consultancy, Research Funding; Genentech-Roch: Consultancy, Research Funding; Gilead: Consultancy; Pharmacyclics, LLC an AbbVie Company: Consultancy, Research Funding; Celgene: Consultancy; Oncternal: Research Funding.